Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth
HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025, on August 19, 2025. Following its return to profitability in 2024, the Company maintained high growth and improved profitability during the reporting period, with core business development and continuous...
First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer
HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso, in combination with chemotherapy for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. The COMPASSION-33 study represents...
DKSH Healthcare Establishes Industry Benchmark in Carbon Emissions Tracking in Thailand
DKSH Business Unit Healthcare has reached a significant milestone in building a more sustainable healthcare supply chain by successfully tracking carbon emissions across its value chain through a collaboration with UOB FinLab's GreenTech Accelerator and Smart Tradzt in Thailand. This achievement also marks the implementation of a reusable cold-chain packaging solution. The...
Vital Materials Released Quantum Flux Photon Counting CT (PCCT) Full Vertical Integration Technology
BEIJING, Aug. 20, 2025 /PRNewswire/ -- From August 15-17, the 31st China International Medical Equipment Exhibition and Scientific Conference (China-Hospeq 2025) was held in Beijing. Vital Materials officially launched the VITA Genesis, China's fully proprietary Photon Counting CT (PCCT) scanner, marking the entry of global medical imaging technology into the "Quantum Flux" sensing era and empowering Chinese innovation in...
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 20, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates...
ARC Therapies Advances Gut Microbiome Research with YB328 Toward Clinical Application
Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy TOKYO, Aug. 20, 2025 /PRNewswire/ -- ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research of YB328, a newly identified gut microbe, toward clinical application. Utilizing its proprietary intellectual property, the company has designated the YB328...
Ping An Good Doctor (1833.HK) Reports Strong Interim Results: Revenue and Profit Accelerate as AI Fuels New Growth Momentum
HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025. During the first half of 2025, the Company delivered steady operational performance, showcasing strong growth momentum with gains in both revenue and profitability....
Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
SHANGHAI, Aug. 19, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the U.S. Food and Drug Administration (FDA). The clearance enables the initiation of Phase I/II study of 7MW4911 to evaluate the safety, pharmacokinetics, and efficacy in patients with advanced colorectal...
LabConnect Launches LabConnector™ to Streamline Lab Data Integration
New service ensures faster, more accurate data delivery to clients JOHNSON CITY, Tenn., Aug. 19, 2025 /PRNewswire/ -- LabConnect, LLC, a global leader in central laboratory services for clinical trials, today announced the launch of LabConnector™, a powerful new technology solution that transforms the way laboratory data is exchanged and managed for clinical...
WuXi Biologics Reports Solid 2025 Interim Results
Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased 11.6% YoY FY25 group revenue growth target raised to 14% – 16% A first-half...
